Breaking News
0
Ad-Free Version. Upgrade your Investing.com experience. Save up to 40% More details

Anteo Diagnostics

By Edison Stock MarketsDec 20, 2013 06:21AM ET
www.investing.com/analysis/anteo-diagnostics-196536
Anteo Diagnostics
By Edison   |  Dec 20, 2013 06:21AM ET
Saved. See Saved Items.
This article has already been saved in your Saved Items
 

A$8m cash with revenue growth
Anteo has raised A$5.5m, issuing 44m shares at 12.5c per share (a 19% discount). This increased cash to A$8m. The funding follows the important collaborative agreement with BBI Solutions to investigate the potential benefits of Mix&Go in point-of-care diagnostic tests. The BBI project is progressing well, with transfer of some material to BBI planned for early in 2014 to allow collaborative work to commence. A successful BBI project during 2014 could lead to a major commercial agreement.

Mix&Go: Surface coating technology
Mix&Go is a proprietary family of metal coordination complexes. Through its Bio-Layer subsidiary, Anteo has optimised a chromium formulation to bind the tails of antibodies irreversibly to synthetic surfaces, including nanoparticles. This means the antibody arms, which specifically bind to the test substance to detect it, are free, which can improve the test’s sensitivity. The technology is covered by granted patents in the US, Europe, Japan and Australia. Anteo saw considerable interest in Mix&Go at the November MEDICA trade fair – the global showcase for diagnostics.

Patents and funding to extend Mix&Go scope
Advantages of using Mix&Go purportedly include simplicity, as well as faster assays with greater sensitivity and improved dynamic range and reduced production costs. Two new patents filed in August 2013 could allow expansion into bioseparations, drug screening, drug delivery and non-health care applications. The new funds will support product development and commercialisation and new business creation.

BBI project: Next generation lateral flow platform
BBI Solutions (part of the global Alere group) is a leading player in immunoassay development and manufacturing services. It provides an extensive portfolio of products and technologies to the global diagnostic and pharmaceutical markets. The project with Anteo evaluates Mix&Go with the nanoparticles and lateral flow technology used in the development of point-of-care tests.

Valuation: EV reflects deal expectations
The placing increases cash to A$8m and gives Anteo an EV of A$114m. The value reflects the market view of the potential of the Mix&Go chemistry linked to BBI’s strong presence in point-of-care tests. It shows Anteo’s ability to conduct deals that may lead it to profitability following successful commercialisation.

To Read the Entire Report Please Click on the pdf File Below.

Anteo Diagnostics
 

Related Articles

Blake Morrow
Disney Setting Up For Fresh Rally Leg By Blake Morrow - Jun 24, 2021

Walt Disney (NYSE:DIS) is setting up well for a fresh rally leg. Solid footing is in place near $168 (Feb/Mar lows). The stock is far from overbought (daily MACD=neutral).  A...

Anteo Diagnostics

Add a Comment

Comment Guidelines

We encourage you to use comments to engage with users, share your perspective and ask questions of authors and each other. However, in order to maintain the high level of discourse we’ve all come to value and expect, please keep the following criteria in mind: 

  • Enrich the conversation
  • Stay focused and on track. Only post material that’s relevant to the topic being discussed.
  • Be respectful. Even negative opinions can be framed positively and diplomatically.
  •  Use standard writing style. Include punctuation and upper and lower cases.
  • NOTE: Spam and/or promotional messages and links within a comment will be removed
  • Avoid profanity, slander or personal attacks directed at an author or another user.
  • Don’t Monopolize the Conversation. We appreciate passion and conviction, but we also believe strongly in giving everyone a chance to air their thoughts. Therefore, in addition to civil interaction, we expect commenters to offer their opinions succinctly and thoughtfully, but not so repeatedly that others are annoyed or offended. If we receive complaints about individuals who take over a thread or forum, we reserve the right to ban them from the site, without recourse.
  • Only English comments will be allowed.

Perpetrators of spam or abuse will be deleted from the site and prohibited from future registration at Investing.com’s discretion.

Write your thoughts here
 
Are you sure you want to delete this chart?
 
Post
Post also to:
 
Replace the attached chart with a new chart ?
1000
Your ability to comment is currently suspended due to negative user reports. Your status will be reviewed by our moderators.
Please wait a minute before you try to comment again.
Thanks for your comment. Please note that all comments are pending until approved by our moderators. It may therefore take some time before it appears on our website.
 
Are you sure you want to delete this chart?
 
Post
 
Replace the attached chart with a new chart ?
1000
Your ability to comment is currently suspended due to negative user reports. Your status will be reviewed by our moderators.
Please wait a minute before you try to comment again.
Add Chart to Comment
Confirm Block

Are you sure you want to block %USER_NAME%?

By doing so, you and %USER_NAME% will not be able to see any of each other's Investing.com's posts.

%USER_NAME% was successfully added to your Block List

Since you’ve just unblocked this person, you must wait 48 hours before renewing the block.

Report this comment

I feel that this comment is:

Comment flagged

Thank You!

Your report has been sent to our moderators for review
Disclaimer: Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. All CFDs (stocks, indexes, futures) and Forex prices are not provided by exchanges but rather by market makers, and so prices may not be accurate and may differ from the actual market price, meaning prices are indicative and not appropriate for trading purposes. Therefore Fusion Media doesn`t bear any responsibility for any trading losses you might incur as a result of using this data.

Fusion Media or anyone involved with Fusion Media will not accept any liability for loss or damage as a result of reliance on the information including data, quotes, charts and buy/sell signals contained within this website. Please be fully informed regarding the risks and costs associated with trading the financial markets, it is one of the riskiest investment forms possible.
Continue with Google
or
Sign up with Email